Scleritis With Uveal Effusion From Alirocumab

Mark P Breazzano; Royce W S Chen

doi:10.7326/L19-0815

Scleritis With Uveal Effusion From Alirocumab

Ann Intern Med. 2020 Jun 16;172(12):834-836. doi: 10.7326/L19-0815. Epub 2020 Mar 10.

Authors

Mark P Breazzano¹, Royce W S Chen²

Affiliations

¹ Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York University School of Medicine, and University Langone Health, New York, New York (M.P.B.).
² Columbia University Irving Medical Center, New York-Presbyterian Hospital, New York, New York (R.W.C.).

PMID: 32150753
DOI: 10.7326/L19-0815

No abstract available

Keywords: Antibody therapy; Intraocular pressure; Monoclonal antibodies; Optic nerve; Retina; Statins; Thyroid; Ultrasound imaging; Vision; Visual acuity.

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects*
Female
Glucocorticoids / administration & dosage
Humans
Hypercholesterolemia / drug therapy*
Middle Aged
Ophthalmic Solutions
Prednisone / administration & dosage
Scleritis / chemically induced*
Scleritis / diagnosis
Scleritis / drug therapy
Slit Lamp Microscopy
Ultrasonography
Uveal Effusion Syndrome / chemically induced*
Uveal Effusion Syndrome / diagnosis
Uveal Effusion Syndrome / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Glucocorticoids
Ophthalmic Solutions
alirocumab
Prednisone